XML 45 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Pay vs Performance Disclosure |  |  |  |  |
Pay vs Performance Disclosure, Table | DODD-FRANK MANDATED PAY VERSUS PERFORMANCE DISCLOSURE As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, the Company must annually disclose in its proxy statement the relationship between Company performance and the “compensation actually paid” (“CAP”) to the Principal Executive Officer (“PEO”) and other NEOs. The following tables and related disclosures contain information regarding PEO CAP and the average CAP to our NEOs for each of the last five years. They also provide information regarding company performance over the same periods and the relationship of CAP to company performance. For information about how the Compensation Committee seeks to align pay with performance when making compensation decisions, see “Compensation Discussion and Analysis.” Pay Versus Performance Table
|  |  |  |  |  |  |  |  |  |  |  | Value of Initial Fixed $100 Investment Based On: |  |  |  |
| Year |  | Summary Compensation Table Total for PEO 1 ($) |  | Compensation Actually Paid to PEO 2,3 ($) |  | Average Summary Compensation Table Total for Non-PEO NEOs 4 ($) |  | Average Compensation Actually Paid to Non-PEO NEOs 3,4,5 ($) |  |  | Total Shareholder Return 6 ($) |  | Peer Group Total Shareholder Return 7 ($) |  |  | GAAP Net Income (Loss) ($ in thousands) |
| 2024 |  | 10,943,571 |  |  | 51,862,690 |  |  | 4,123,249 |  |  | 19,665,192 |  |  |  | 289 |  |  | 114 |  |  |  | (913,772) |  |
| 2023 |  | 10,411,260 |  |  | 17,719,035 |  |  | 4,169,997 |  |  | 7,124,646 |  |  |  | 130 |  |  | 115 |  |  |  | (749,567) |  |
| 2022 |  | 7,789,898 |  |  | 4,334,915 |  |  | 3,964,362 |  |  | 2,740,466 |  |  |  | 84 |  |  | 111 |  |  |  | (481,534) |  |
| 2021 |  | 7,322,642 |  |  | 2,807,467 |  |  | 3,323,439 |  |  | 1,870,969 |  |  |  | 114 |  |  | 125 |  |  |  | (434,654) |  |
| 2020 |  | 6,185,704 |  |  | 12,656,157 |  |  | 2,839,276 |  |  | 4,418,181 |  |  |  | 139 |  |  | 126 |  |  |  | (294,090) |  |
1.Reflects compensation (as reported in the Summary Compensation Table (“SCT”)) for our Chair and CEO, Mr. Lewis, who served as our PEO in all five years. 2.Calculated in accordance with Item 402(v)(2) of Regulation S-K. The following adjustments were made to Mr. Lewis’s 2024 SCT total compensation as reported in the SCT for each year to determine CAP.
| Year |  | Summary Compensation Table Total ($) |  | Deductions for Reported Grant Date Fair Value of Stock Awards A ($) |  | Deductions for Reported Grant Date Fair Value of Option Awards A ($) |  | Additions for Pay Versus Performance Equity Adjustments B ($) |  | Compensation Actually Paid ($) |
| 2024 |  | 10,943,571 |  |  | (2,206,246) |  |  | (6,618,734) |  |  | 49,744,099 |  |  | 51,862,690 |  |
| 2023 |  | 10,411,260 |  |  | (2,206,232) |  |  | (6,616,654) |  |  | 16,130,661 |  |  | 17,719,035 |  |
| 2022 |  | 7,789,898 |  |  | (1,624,982) |  |  | (4,872,967) |  |  | 3,042,966 |  |  | 4,334,915 |  |
| 2021 |  | 7,322,642 |  |  | (1,499,969) |  |  | (4,499,673) |  |  | 1,484,467 |  |  | 2,807,467 |  |
| 2020 |  | 6,185,704 |  |  | (1,249,986) |  |  | (3,749,998) |  |  | 11,470,437 |  |  | 12,656,157 |  |
A.Reflects the amounts reported in the Stock Awards and Option Awards columns of the SCT. B.The pay versus performance equity adjustments reflect the aggregated sum of the following values for the respective years.
| Year |  | Year-End Fair Value of Outstanding and Unvested Equity Awards Granted in the Covered Year ($) |  | Year Over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years ($) |  | Year Over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Covered Year ($) |  | Total Pay Versus Performance Equity Adjustments C ($) |
| 2024 |  | 24,325,157 |  |  | 21,706,769 |  |  | 3,712,173 |  |  | 49,744,099 |  |
| 2023 |  | 13,669,229 |  |  | 2,745,355 |  |  | (283,923) |  |  | 16,130,661 |  |
| 2022 |  | 6,205,073 |  |  | (2,171,008) |  |  | (991,099) |  |  | 3,042,966 |  |
| 2021 |  | 5,178,718 |  |  | (2,774,420) |  |  | (919,831) |  |  | 1,484,467 |  |
| 2020 |  | 7,254,113 |  |  | 3,693,320 |  |  | 523,003 |  |  | 11,470,437 |  |
C.Amounts may not sum due to rounding of underlying elements for reporting purposes. 1.Measurement date equity fair values are calculated with assumptions derived on a basis consistent with those used for grant date fair value purposes. RSUs are valued based on the closing stock price on the relevant measurement date. PSUs are valued with an assumed payout factor of 0%, consistent with the assumption for ASC 718 purposes. Stock options are valued using a Black-Scholes model as at the relevant measurement dates. 2.Reflects compensation for the following non-PEO NEOs: 2022, 2023 and 2024: Ms. Bonstein, Mr. Adsett, Dr. Flammer, and Mr. Wise 2021: Ms. Bonstein, Mr. Adsett, Dr. Flammer, Ms. Schaeffer, and Ms. Pellizzari 2020: Ms. Bonstein, Mr. Adsett, Dr. Flammer, Ms. Pellizzari, and Mr. Goll 3.Average CAP for the non-PEO NEOs has been calculated in accordance with Item 402(v)(2) of Regulation S-K. The following adjustments were made to average 2024 SCT total compensation for each year to determine average CAP.
| Year |  | Average Summary Compensation Table Total ($) |  | Deductions for Average Reported Grant Date Fair Value of Stock Awards a ($) |  | Deductions for Average Reported Grant Date Fair Value of Option Awards a ($) |  | Additions for Average Pay Versus Performance Equity Adjustments b ($) |  | Average Compensation Actually Paid c ($) |
| 2024 |  | 4,123,249 |  |  | (749,990) |  |  | (2,250,057) |  |  | 18,541,990 |  |  | 19,665,192 |  |
| 2023 |  | 4,169,997 |  |  | (978,097) |  |  | (2,296,135) |  |  | 6,228,880 |  |  | 7,124,646 |  |
| 2022 |  | 3,964,362 |  |  | (765,603) |  |  | (2,425,635) |  |  | 1,967,342 |  |  | 2,740,466 |  |
| 2021 |  | 3,323,439 |  |  | (662,479) |  |  | (1,987,359) |  |  | 1,197,368 |  |  | 1,870,969 |  |
| 2020 |  | 2,839,276 |  |  | (324,990) |  |  | (1,779,836) |  |  | 3,683,731 |  |  | 4,418,181 |  |
a.Reflects the average amounts reported in the Stock Awards and Option Awards columns of the SCT. b.The pay versus performance equity adjustments reflect the aggregated sum of the following values for the respective years.
| Year |  | Average Year-End Fair Value of Outstanding and Unvested Equity Awards Granted in the Covered Year ($) |  | Average Year Over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years ($) |  | Average Year Over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Covered Year ($) |  | Total Pay Versus Performance Equity Adjustments c ($) |
| 2024 |  | 8,269,342 |  |  | 8,764,796 |  |  | 1,507,852 |  |  | 18,541,990 |  |
| 2023 |  | 5,088,247 |  |  | 1,245,859 |  |  | (105,226) |  |  | 6,228,880 |  |
| 2022 |  | 3,073,419 |  |  | (725,458) |  |  | (380,618) |  |  | 1,967,342 |  |
| 2021 |  | 2,293,306 |  |  | (852,103) |  |  | (243,835) |  |  | 1,197,368 |  |
| 2020 |  | 2,962,880 |  |  | 630,498 |  |  | 90,353 |  |  | 3,683,731 |  |
c.Amounts may not sum due to rounding of underlying elements for reporting purposes. i.Total shareholder return is the only financial performance measure that is currently, and was through the years presented in the table, used in incentive plans to link CAP to Company performance. ii.The Nasdaq Biotech Index is the selected Peer Group for TSR comparisons as included on the total return chart included on our Annual Report on Form 10-K for each reported year. |  |  |  |
Company Selected Measure Name | Total shareholder return |  |  |  |
Named Executive Officers, Footnote | 1.Reflects compensation (as reported in the Summary Compensation Table (“SCT”)) for our Chair and CEO, Mr. Lewis, who served as our PEO in all five years. 2.Reflects compensation for the following non-PEO NEOs: 2022, 2023 and 2024: Ms. Bonstein, Mr. Adsett, Dr. Flammer, and Mr. Wise 2021: Ms. Bonstein, Mr. Adsett, Dr. Flammer, Ms. Schaeffer, and Ms. Pellizzari |  |  |  |
Peer Group Issuers, Footnote | ii.The Nasdaq Biotech Index is the selected Peer Group for TSR comparisons as included on the total return chart included on our Annual Report on Form 10-K for each reported year. |  |  |  |
PEO Total Compensation Amount | $ 10,943,571 | $ 10,411,260 | $ 7,789,898 | $ 7,322,642 | $ 6,185,704
PEO Actually Paid Compensation Amount | $ 51,862,690 | 17,719,035 | 4,334,915 | 2,807,467 | 12,656,157
Adjustment To PEO Compensation, Footnote | 2.Calculated in accordance with Item 402(v)(2) of Regulation S-K. The following adjustments were made to Mr. Lewis’s 2024 SCT total compensation as reported in the SCT for each year to determine CAP.
| Year |  | Summary Compensation Table Total ($) |  | Deductions for Reported Grant Date Fair Value of Stock Awards A ($) |  | Deductions for Reported Grant Date Fair Value of Option Awards A ($) |  | Additions for Pay Versus Performance Equity Adjustments B ($) |  | Compensation Actually Paid ($) |
| 2024 |  | 10,943,571 |  |  | (2,206,246) |  |  | (6,618,734) |  |  | 49,744,099 |  |  | 51,862,690 |  |
| 2023 |  | 10,411,260 |  |  | (2,206,232) |  |  | (6,616,654) |  |  | 16,130,661 |  |  | 17,719,035 |  |
| 2022 |  | 7,789,898 |  |  | (1,624,982) |  |  | (4,872,967) |  |  | 3,042,966 |  |  | 4,334,915 |  |
| 2021 |  | 7,322,642 |  |  | (1,499,969) |  |  | (4,499,673) |  |  | 1,484,467 |  |  | 2,807,467 |  |
| 2020 |  | 6,185,704 |  |  | (1,249,986) |  |  | (3,749,998) |  |  | 11,470,437 |  |  | 12,656,157 |  |
A.Reflects the amounts reported in the Stock Awards and Option Awards columns of the SCT. B.The pay versus performance equity adjustments reflect the aggregated sum of the following values for the respective years.
| Year |  | Year-End Fair Value of Outstanding and Unvested Equity Awards Granted in the Covered Year ($) |  | Year Over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years ($) |  | Year Over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Covered Year ($) |  | Total Pay Versus Performance Equity Adjustments C ($) |
| 2024 |  | 24,325,157 |  |  | 21,706,769 |  |  | 3,712,173 |  |  | 49,744,099 |  |
| 2023 |  | 13,669,229 |  |  | 2,745,355 |  |  | (283,923) |  |  | 16,130,661 |  |
| 2022 |  | 6,205,073 |  |  | (2,171,008) |  |  | (991,099) |  |  | 3,042,966 |  |
| 2021 |  | 5,178,718 |  |  | (2,774,420) |  |  | (919,831) |  |  | 1,484,467 |  |
| 2020 |  | 7,254,113 |  |  | 3,693,320 |  |  | 523,003 |  |  | 11,470,437 |  |
C.Amounts may not sum due to rounding of underlying elements for reporting purposes. |  |  |  |
Non-PEO NEO Average Total Compensation Amount | $ 4,123,249 | 4,169,997 | 3,964,362 | 3,323,439 | 2,839,276
Non-PEO NEO Average Compensation Actually Paid Amount | $ 19,665,192 | 7,124,646 | 2,740,466 | 1,870,969 | 4,418,181
Adjustment to Non-PEO NEO Compensation Footnote | 3.Average CAP for the non-PEO NEOs has been calculated in accordance with Item 402(v)(2) of Regulation S-K. The following adjustments were made to average 2024 SCT total compensation for each year to determine average CAP.
| Year |  | Average Summary Compensation Table Total ($) |  | Deductions for Average Reported Grant Date Fair Value of Stock Awards a ($) |  | Deductions for Average Reported Grant Date Fair Value of Option Awards a ($) |  | Additions for Average Pay Versus Performance Equity Adjustments b ($) |  | Average Compensation Actually Paid c ($) |
| 2024 |  | 4,123,249 |  |  | (749,990) |  |  | (2,250,057) |  |  | 18,541,990 |  |  | 19,665,192 |  |
| 2023 |  | 4,169,997 |  |  | (978,097) |  |  | (2,296,135) |  |  | 6,228,880 |  |  | 7,124,646 |  |
| 2022 |  | 3,964,362 |  |  | (765,603) |  |  | (2,425,635) |  |  | 1,967,342 |  |  | 2,740,466 |  |
| 2021 |  | 3,323,439 |  |  | (662,479) |  |  | (1,987,359) |  |  | 1,197,368 |  |  | 1,870,969 |  |
| 2020 |  | 2,839,276 |  |  | (324,990) |  |  | (1,779,836) |  |  | 3,683,731 |  |  | 4,418,181 |  |
a.Reflects the average amounts reported in the Stock Awards and Option Awards columns of the SCT. b.The pay versus performance equity adjustments reflect the aggregated sum of the following values for the respective years.
| Year |  | Average Year-End Fair Value of Outstanding and Unvested Equity Awards Granted in the Covered Year ($) |  | Average Year Over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years ($) |  | Average Year Over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Covered Year ($) |  | Total Pay Versus Performance Equity Adjustments c ($) |
| 2024 |  | 8,269,342 |  |  | 8,764,796 |  |  | 1,507,852 |  |  | 18,541,990 |  |
| 2023 |  | 5,088,247 |  |  | 1,245,859 |  |  | (105,226) |  |  | 6,228,880 |  |
| 2022 |  | 3,073,419 |  |  | (725,458) |  |  | (380,618) |  |  | 1,967,342 |  |
| 2021 |  | 2,293,306 |  |  | (852,103) |  |  | (243,835) |  |  | 1,197,368 |  |
| 2020 |  | 2,962,880 |  |  | 630,498 |  |  | 90,353 |  |  | 3,683,731 |  |
c.Amounts may not sum due to rounding of underlying elements for reporting purposes. |  |  |  |
Compensation Actually Paid vs. Total Shareholder Return | Compensation Actually Paid Versus Company Performance The following graph visually describes the relationship between CAP to our PEO and the average CAP to our non-PEO NEOs, to the cumulative TSR of Insmed. In addition, it compares the cumulative TSR of Insmed to our selected peer group, the Nasdaq Biotech Index. |  |  |  |
Compensation Actually Paid vs. Net Income | Compensation Actually Paid Versus Company Performance The following graph visually describes the relationship between CAP to our PEO and the average CAP to our non-PEO NEOs, to GAAP net income (loss). Insmed does not consider GAAP net income (loss) as a relevant measure for determining our executive compensation given the lifecycle stage of our company. The movement in CAP across the four-year time horizon does not move meaningfully or deliberately in relation to the reported GAAP net income (loss). |  |  |  |
Compensation Actually Paid vs. Company Selected Measure | Compensation Actually Paid Versus Company Performance The following graph visually describes the relationship between CAP to our PEO and the average CAP to our non-PEO NEOs, to the cumulative TSR of Insmed. In addition, it compares the cumulative TSR of Insmed to our selected peer group, the Nasdaq Biotech Index. |  |  |  |
Total Shareholder Return Vs Peer Group | Compensation Actually Paid Versus Company Performance The following graph visually describes the relationship between CAP to our PEO and the average CAP to our non-PEO NEOs, to the cumulative TSR of Insmed. In addition, it compares the cumulative TSR of Insmed to our selected peer group, the Nasdaq Biotech Index. |  |  |  |
Tabular List, Table | Tabular List of Company Performance Measures As further described in our CD&A, we believe that the compensation opportunities for our NEOs should be predominantly variable with a significant portion in the form of short-term and long-term incentives. Given the current life-cycle stage of Insmed, financial measures do not feature meaningfully in our incentive plan design, which instead focuses on pipeline progress across our four pillars and stock price performance. For the fiscal year ending December 31, 2024, the only financial performance measure used to link CAP to our NEOs to company performance was total shareholder return. Total shareholder return was used on a relative basis to assess performance in respect of the PSUs, which were unvested and outstanding, at the conclusion of the performance period. As a result of total shareholder return already being included in the pay versus performance table, no company-selected measure is reported.
| TABULAR LIST OF MOST IMPORTANT MEASURES |
(1) | Total Shareholder Return
Total Shareholder Return Amount | $ 289 | 130 | 84 | 114 | 139
Peer Group Total Shareholder Return Amount | 114 | 115 | 111 | 125 | 126
Net Income (Loss) | $ (913,772,000) | $ (749,567,000) | $ (481,534,000) | $ (434,654,000) | (294,090,000)
PEO Name | Mr. Lewis | Mr. Lewis | Mr. Lewis | Mr. Lewis |
Measure:: 1 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Total Shareholder Return |  |  |  |
PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ 49,744,099 | $ 16,130,661 | $ 3,042,966 | $ 1,484,467 | 11,470,437
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 24,325,157 | 13,669,229 | 6,205,073 | 5,178,718 | 7,254,113
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 21,706,769 | 2,745,355 | (2,171,008) | (2,774,420) | 3,693,320
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 3,712,173 | (283,923) | (991,099) | (919,831) | 523,003
PEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Stock Awards [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (2,206,246) | (2,206,232) | (1,624,982) | (1,499,969) | (1,249,986)
PEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Option Awards [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (6,618,734) | (6,616,654) | (4,872,967) | (4,499,673) | (3,749,998)
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 18,541,990 | 6,228,880 | 1,967,342 | 1,197,368 | 3,683,731
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 5,088,247 | 3,073,419 | 2,293,306 | 2,962,880 |
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 1,245,859 | (725,458) | (852,103) | 630,498 |
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (105,226) | (380,618) | (243,835) | 90,353 |
Non-PEO NEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Stock Awards [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (749,990) | (978,097) | (765,603) | (662,479) | (324,990)
Non-PEO NEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Option Awards [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (2,250,057) | (2,296,135) | (2,425,635) | (1,987,359) | $ (1,779,836)
Non-PEO NEO | Pay Versus Performance Equity Adjustments [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ 6,228,880 | $ 1,967,342 | $ 1,197,368 | $ 3,683,731 |

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=insm_AggregateGrantDateFairValueOfEquityAwardAmountsReportedInSummaryCompensationTableStockAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=insm_AggregateGrantDateFairValueOfEquityAwardAmountsReportedInSummaryCompensationTableOptionAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=insm_PayVersusPerformanceEquityAdjustmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |